Claire Szipszky1, Daniel Van Aartsen2, Sarah Criddle3, Prakruti Rao2, Isaac Zentner4, Museveni Justine5, Estomih Mduma5, Stellah Mpagama6, Mohammad H Al-Shaer7, Charles Peloquin7, Tania A Thomas2, Christopher Vinnard4, Scott K Heysell2. 1. Departments of Biology and Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA. 2. Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA. 3. School of Medicine, University of Virginia, Charlottesville, Virginia, USA. 4. Public Health Research Institute, Rutgers State University of New Jersey, Newark, New Jersey, USA. 5. Haydom Lutheran Hospital, Haydom, Tanzania. 6. Kibong'oto Infectious Diseases Hospital, Sanya Juu, Kilimanjaro, Tanzania. 7. Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Abstract
BACKGROUND: Individual pharmacokinetic variability is a driver of poor tuberculosis (TB) treatment outcomes. We developed a method for measurement of rifampin concentrations by urine colorimetry and a mobile phone photographic application to predict clinically important serum rifampin pharmacokinetic measurements in children treated for TB. METHODS: Among spiked urine samples, colorimetric assay performance was tested with conventional spectrophotometric and the mobile phone/light box methods under various environmental and biologic conditions. Urine rifampin absorbance (Abs) was then determined from timed specimens from children treated for TB in Tanzania, and compared to serum pharmacokinetic measurements collected throughout the dosing interval. RESULTS: Both the mobile phone/light box and spectrophotometry demonstrated excellent correlation across a wide range of urine rifampin concentrations (7.8-1000 mg/L) in intra- and interday trials, 24-hour exposure to ambient light or darkness, and varying urinalysis profiles (all r ≥ 0.98). In 12 Tanzanian children, the urine mobile phone/light box measurement and serum peak concentration (Cmax) were significantly correlated (P = .004). Using a Cmax target of 8 mg/L, the area under the receiver operating characteristic curve was 80.1% (range, 47.2%-100%). A urine mobile phone/light box threshold of 50 Abs correctly classified all patients (n = 6) with serum measurements below target. CONCLUSIONS: The urine colorimetry with mobile phone/light box assay accurately measured rifampin absorbance in varying environmental and biological conditions that may be observed clinically. Among children treated for TB, the assay was sensitive for detection of low rifampin serum concentrations. Future work will identify the optimal timing for urine collection, and operationalize use in TB-endemic settings.
BACKGROUND: Individual pharmacokinetic variability is a driver of poor tuberculosis (TB) treatment outcomes. We developed a method for measurement of rifampin concentrations by urine colorimetry and a mobile phone photographic application to predict clinically important serum rifampin pharmacokinetic measurements in children treated for TB. METHODS: Among spiked urine samples, colorimetric assay performance was tested with conventional spectrophotometric and the mobile phone/light box methods under various environmental and biologic conditions. Urine rifampin absorbance (Abs) was then determined from timed specimens from children treated for TB in Tanzania, and compared to serum pharmacokinetic measurements collected throughout the dosing interval. RESULTS: Both the mobile phone/light box and spectrophotometry demonstrated excellent correlation across a wide range of urine rifampin concentrations (7.8-1000 mg/L) in intra- and interday trials, 24-hour exposure to ambient light or darkness, and varying urinalysis profiles (all r ≥ 0.98). In 12 Tanzanian children, the urine mobile phone/light box measurement and serum peak concentration (Cmax) were significantly correlated (P = .004). Using a Cmax target of 8 mg/L, the area under the receiver operating characteristic curve was 80.1% (range, 47.2%-100%). A urine mobile phone/light box threshold of 50 Abs correctly classified all patients (n = 6) with serum measurements below target. CONCLUSIONS: The urine colorimetry with mobile phone/light box assay accurately measured rifampin absorbance in varying environmental and biological conditions that may be observed clinically. Among children treated for TB, the assay was sensitive for detection of low rifampin serum concentrations. Future work will identify the optimal timing for urine collection, and operationalize use in TB-endemic settings.
Authors: Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona Journal: Lancet Date: 2010-05-22 Impact factor: 79.321
Authors: Isaac Zentner; Chawangwa Modongo; Nicola M Zetola; Jotam G Pasipanodya; Shashikant Srivastava; Scott K Heysell; Stellah Mpagama; Hans P Schlect; Tawanda Gumbo; Gregory P Bisson; Christopher Vinnard Journal: Int J Infect Dis Date: 2017-12-15 Impact factor: 3.623
Authors: Ben J Marais; Robert P Gie; H Simon Schaaf; Nulda Beyers; Peter R Donald; Jeff R Starke Journal: Am J Respir Crit Care Med Date: 2006-02-16 Impact factor: 21.405
Authors: K E Stott; H Pertinez; M G G Sturkenboom; M J Boeree; R Aarnoutse; G Ramachandran; A Requena-Méndez; C Peloquin; C F N Koegelenberg; J W C Alffenaar; R Ruslami; A Tostmann; S Swaminathan; H McIlleron; G Davies Journal: J Antimicrob Chemother Date: 2018-09-01 Impact factor: 5.790
Authors: Isaac Zentner; Hans P Schlecht; Lorna Khensouvann; Neo Tamuhla; Michele Kutzler; Vijay Ivaturi; Jotam G Pasipanodya; Tawanda Gumbo; Charles A Peloquin; Gregory P Bisson; Christopher Vinnard Journal: BMC Infect Dis Date: 2016-06-01 Impact factor: 3.090
Authors: O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-07-01 Impact factor: 3.427
Authors: Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar Journal: Ther Drug Monit Date: 2022-02-01 Impact factor: 3.118
Authors: J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427
Authors: Bibie N Said; Scott K Heysell; Getnet Yimer; Rob E Aarnoutse; Gibson S Kibiki; Stellah Mpagama; Peter M Mbelele Journal: Int J Mycobacteriol Date: 2021 Oct-Dec
Authors: Prakruti Rao; Svetlana Zhdanova; Oleg Ogarkov; Elizaveta Orlova; Andrew Ebers; Suzanne Stroup; Shino Mirawdaly; Daniel Van Aartsen; Olga Koshkina; Alexey Suzdalnitsky; Elena Moiseeva; Rebecca Dillingham; Scott K Heysell Journal: Int J Mycobacteriol Date: 2020 Oct-Dec